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Detection of 51 Human Papillomavirus Genotypes
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Van Doorn6, The CVT Group, Allan Hildesheim,1 Mark Schiffman,1 and Nicolas Wentzensen1,
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland; 2Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos 
Biomedical Research Inc., Maryland; 3University of Oklahoma Health Sciences Center, Oklahoma City; 4Agencia Costarricense de Investigaciones Biomedicas, San José, Costa Rica; 5International 
Agency for Research on Cancer, World Health Organization, Lyon, France; 6DDL Diagnostic Laboratory, Rijswijk, The Netherlands
Background. Human papillomaviruses (HPV) cause over 500  000 cervical cancers each year, most of which occur in low-
resource settings. Human papillomavirus genotyping is important to study natural history and vaccine efficacy. We evaluated 
TypeSeq, a novel, next-generation, sequencing-based assay that detects 51 HPV genotypes, in 2 large international epidemiologic 
studies.
Methods. TypeSeq was evaluated in 2804 cervical specimens from the Study to Understand Cervical Cancer Endpoints and 
Early Determinants (SUCCEED) and in 2357 specimens from the Costa Rica Vaccine Trial (CVT). Positive agreement and risks of 
precancer for individual genotypes were calculated for TypeSeq in comparison to Linear Array (SUCCEED). In CVT, positive agree-
ment and vaccine efficacy were calculated for TypeSeq and SPF10-LiPA.
Results. We observed high overall and positive agreement for most genotypes between TypeSeq and Linear Array in SUCCEED 
and SPF10-LiPA in CVT. There was no significant difference in risk of precancer between TypeSeq and Linear Array in SUCCEED 
or in estimates of vaccine efficacy between TypeSeq and SPF10-LiPA in CVT.
Conclusions. The agreement of TypeSeq with Linear Array and SPF10-LiPA, 2 well established standards for HPV genotyping, 
demonstrates its high accuracy. TypeSeq provides high-throughput, affordable HPV genotyping for world-wide studies of cervical 
precancer risk and of HPV vaccine efficacy.
Keywords.  HPV; TypeSeq; vaccine efficacy; genotyping; screening.
Human papillomaviruses (HPV) are a major cause of inva-
sive cancers world-wide, with up to 600 000 cancers related to 
HPV occurring in 2012, 500 000 of which were cervical can-
cers. Less common HPV-related cancer sites include the vulva, 
vagina, anus, penis, and oral cavity [1]. Over 200 HPV geno-
types have been identified so far that vary by tissue tropism and 
carcinogenic potential. Only a small group of 12–13 types is 
responsible for most HPV-related cancers (referred to as high 
risk [HR] or carcinogenic types). Risk of precancer and cancer 
varies substantially within this group. HPV16 is by far the most 
carcinogenic type, causing over 60% of invasive cervical can-
cers and most HPV-related noncervical cancers, followed by 
HPV18 (15% of cervical cancers). At the cervix, both HPV16 
and HPV18 increase in relative prevalence from HPV infec-
tions to precancers and cancers [2].
Detection of individual HPV genotypes associated with infec-
tions is important for research and, to some degree, for clinical 
use [3–5]. Epidemiologic research regarding the natural history 
of HPV depends on typing, because transmission, clearance, 
transformation, and invasive potential may differ by genotype. 
In a clinical setting, HPV testing is more efficient than the Pap 
test for primary cervical cancer screening [4, 6–9]. Evaluation 
of type-specific risk for precancer and cancer is necessary to de-
cide which genotypes should be included in HPV assays and 
which genotypes should be detected individually. Recently ap-
proved assays use partial genotyping for HPV16 and HPV18 
(and sometimes HPV45) for additional risk stratification [10]; 
more extended genotyping is under consideration.
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Typing is important to estimate HPV vaccine efficacy (VE) 
[11]. Human papillomavirus vaccine trials and postvaccination 
surveillance programs require accurate and reliable HPV 
genotyping assays that detect a wide range of genotypes that are 
either (1) directly targeted by the vaccine, (2) targets of cross-
protection, or (3) not directly or indirectly affected by vaccines 
[11]. There is a growing public health need for reliable, low-cost 
HPV genotyping methods applicable to large populations.
Few commercial assays are currently available for HPV 
genotyping, and most are laborious, low-throughput, and ex-
pensive. Next-generation sequencing (NGS) technology pro-
vides massively parallel sequencing capacity that can be used 
for detection of viral deoxyribonucleic acid (DNA) in clinical 
specimens. We recently developed TypeSeq, a novel NGS-based 
HPV genotyping assay that allows for highly automated, high-
throughput testing at low cost [12]. In this study, we present the 
validation of TypeSeq in 2 large studies with a focus on detec-
tion of cervical precancers and on estimating VE.
METHODS
Study Descriptions
Human papillomavirus genotyping was performed in 2804 sam-
ples from women enrolled in the Study to Understand Cervical 
Cancer Early Endpoints and Determinants (SUCCEED) and in 
2357 samples from women enrolled into the Costa Rica HPV 
Vaccine Trial (CVT). Of note, 1000 samples were randomly 
selected from each arm in CVT, and the remaining 357 samples 
were enriched for SPF-10 HPV16/18-positive samples. 
This study is registered with Clinicaltrials.gov 
(NCT00128661). GlaxoSmithKline Biologicals provided vac-
cine and support for aspects of the trial associated with regu-
latory submission needs of the company under a Clinical Trials 
Agreement (FDA BB-IND 7920)  during the 4-year, random-
ized, blinded phase of our study.
SUCCEED Population, DNA Extraction, and Linear Array Genotyping
SUCCEED was a cross-sectional study of women 18 years of age 
or older with an abnormal Pap smear who were referred to col-
poscopy or treatment at the University of Oklahoma (OUHSC) 
between 2003 and 2011. Written informed consent was obtained 
from all women enrolled in the study, and Institutional Review 
Board approval was provided by OUHSC and the US National 
Cancer Institute (NCI) [13]. 
The DNA isolation method used for SUCCEED has been de-
scribed previously [14]. Linear Array HPV Genotyping System 
(Roche Molecular Diagnostics) genotyping was performed as de-
scribed previously [14–16]. Up to 80 patient specimens, 3 HPV16-
positive controls, and 1 HPV-negative control were amplified in 
each batch using the Linear Array (LA). Detection of both β-globin 
concentration control probes was required to report genotyping 
results. A hybridization signal was called “positive” when an un-
ambiguous, continuous band was observed on the array.
CVT Population, DNA Extraction, and SPF10-LiPA Genotyping
The CVT was a community-based, double-blind, randomized, 
controlled phase III trial of the bivalent vaccine (Cervarix). As 
previously described, 18- to 25-year-old women residing in the 
provinces of Guanacaste and Puntarenas, Costa Rica, identified 
via a population census specifically conducted for the study, 
were invited to participate by attending a study clinic [17]. The 
trial was approved by human subjects review committees of the 
NCI and Instituto Costarricense de Investigación y Enseñanza 
en Nutrición y Salud ([INCIENSA] Costa Rica).
Extracted DNA from cervical specimens was polymerase 
chain reaction (PCR)-amplified and hybridized to HPV-specific 
probes using the SPF10 HPV DNA enzyme immunoassay 
(DEIA) system and the LiPA25, version 1, line detection system 
(SPF10 DEIA/LiPA25/TS16/18 system) [17, 18], following the 
manufacturer’s instructions. In addition, all specimens positive 
for HPV DNA using SPF10 DEIA but negative for HPV16 or 
HPV18 by LiPA25 were also tested with type-specific primers/
probes for the presence of HPV16 and HPV18 DNA [18, 19].
TypeSeq Genotyping
TypeSeq is able to detect the following 51 types: HPV3, 6, 11, 
13, 16, 18, 26, 28, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 
52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 
81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 97, 114 (see Supplementary 
Table 1). Up to 950 patient specimens, 12 HPV-positive con-
trol pools, 2 HPV-negative human-positive controls, and 2 
no-template controls were processed per batch, with 1 addi-
tional no-template control randomly located on each 96-well 
plate of specimens. Human beta-2-microglobulin (B2M) gene 
(GenBank accession number NG_012920) served as the in-
ternal positive control in each reaction.
In brief, the stage 1 (S1) type-specific multiplex amplification 
and copy number standardization PCR was performed in a final 
reaction volume of 12  µL, containing 5  µL purified genomic 
DNA. The S1 primer pool contained 127 RNase H2-dependent 
primers (Integrated DNA Technologies, Coralville, IA), 
targeting 1 human gene (B2M) and a region of the L1 gene. The 
S2 primer pool contained nested B2M primers and 170 nested 
HPV unmodified primers (Integrated DNA Technologies). 
After cycling, unincorporated primers were degraded with 
Exonuclease I (Lucigen, Middleton, WI), then 2 µL was used as 
template for the 10-µL stage 3 (S3) PCR. During the S3 PCR, Ion 
sequencing adapters and dual barcodes were incorporated into 
amplicons via the universal priming sites. The PCR products 
were pooled and purified, then sequenced on the Ion S5 plat-
form (Thermo Fisher Scientific, Waltham, MA) according to 
the manufacturer’s instructions. Dual barcode demultiplexing, 
quality filtering and HPV genotyping detection were per-
formed using a custom plugin developed in-house, run within 
the Torrent Suite software (Thermo Fisher Scientific). A min-
imum of 850 total HPV reads or 300 B2M reads per sample was 
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required to report genotyping results, otherwise the sample was 
reported as “failed to amplify”. Positive HPV type calls required 
a minimum of 127–212 reads, depending on type.
Five hundred fifty-eight CVT specimens were tested in 
2 independent batches on different days to assess TypeSeq 
interbatch reproducibility. Batch 1 was performed using manual 
pipetting, and batch 2 was done by automated pipetting using a 
JANUS liquid handler (PerkinElmer, Waltham, MA).
Statistical Analysis
We calculated overall agreement and positive agreement be-
tween TypeSeq and LA genotyping in SUCCEED, and between 
TypeSeq and SPF10-LiPA genotyping in CVT, and we calcu-
lated McNemar P values. We further evaluated agreement be-
tween hierarchical categories of HPV positivity between the 
paired tests, combining any carcinogenic type (HR+), other 
HPV types, and types only detected by TypeSeq but not by the 
paired assay. We compared the observed frequencies of 2-type 
combinations for the 37 genotypes detected by LA and for the 
51 genotypes detected by TypeSeq with expected frequencies in 
all women with at least 2 concurrent HPV infections. To obtain 
expected frequencies for a 2-type combination, the observed 
genotype frequencies for both types were multiplied and the re-
sult was multiplied with the total number of subjects.
In SUCCEED, we compared the risk of precancer and cancer 
(cervical intraepithelial neoplasia [CIN]3+) for each genotype 
as determined by TypeSeq and LA. For testing statistical sig-
nificance, we compared the proportion of TS+/LA− and TS−/
LA+ samples that were positive for CIN3+ using Fisher’s exact 
test. To evaluate the performance of the assay for HPV vaccina-
tion studies, we recomputed VE at the 4-year study visit in CVT 
using HPV results generated by TypeSeq and compared these 
estimates to those obtained in the initial round of testing using 
the SPF10 DEIA/LiPA25/TS16/18 system. Vaccine efficacy 
against one-time detection of HPV16/18, HPV31/33/45, and 
other carcinogenic HPV types (excluding HPV16, 18, 31, 33, 
and 45) based on the TypeSeq and SPF10 tests in the intention-
to-treat cohort (all vaccinated women) was computed. For 
each arm, we defined the prevalence as the proportion of the 
number of events among the number of women at the 4-year 
study visit. The complement of the ratios of the HPV prevalence 
in the HPV arm and the control arm are the VE estimates. We 
calculated these VE estimates within the randomly sampled 
population and weighted back to the entire CVT. Exact confi-
dence intervals (CIs) [20] for VE were calculated based on the 
binomial distribution of the number of events in the HPV arm 
among the total number of events in the HPV and control arms 
[21]. Vaccine efficacy obtained by the SPF10-LiPA system was 
predefined as the comparator. The prespecified goal of the anal-
ysis was that the 95% CI of the TypeSeq VE estimate included 
the SPF10-LiPA/DEIA VE point estimate, to assure compara-
bility of the VE estimates between both tests.
RESULTS
Prevalence of 51 Human Papillomavirus Genotypes Detected by TypeSeq 
in SUCCEED and CVT
We evaluated TypeSeq results of cervical samples from 2804 
women enrolled in SUCCEED and from 2357 women enrolled 
in CVT, respectively. In SUCCEED, a colposcopy referral pop-
ulation enriched for precancers and cancers, most women were 
HPV positive and HPV16 was by far the most common type 
(Figure 1). Among the 37 HPV genotypes detected by both 
TypeSeq and LA, the number of infections detected was very 
similar for both assays. The most common types detected by 
TypeSeq not included in LA were HPV30, 43, 74, 87, 90, 91, and 
114; none has known strong disease associations. In CVT, an 
HPV vaccination trial of young women, a large proportion of 
women were negative for all 51 types detected using TypeSeq. 
For most of the 26 types detected by both TypeSeq and SPF10-
LiPA, the number of infections was similar for both assays 
(Figure 2). To evaluate possible cross-reactivity between HPV 
genotypes, we compared observed versus expected numbers 
of 2‐genotype combinations detected by LA and TypeSeq in 
SUCCEED. With LA, we observed substantially more combin-
ations of HPV56 and HPV66, which are closely related and have 
been previously described to cross-react (see Supplementary 
Figure 1A) [15]. In contrast, there was no type combination ob-
served substantially more frequently than expected for TypeSeq, 
suggesting no cross-reactivity (see Supplementary Figure 1B).
To assess TypeSeq reproducibility on clinical specimens, we 
tested 558 CVT specimens in duplicate using manual and au-
tomated processing (Table 1). Agreements for testing positive 
were 93.1% for any HR type, 93.2% for HPV16/18 combined, 
and ranged from 71.4% (HPV59) to 100% (HPV58) for indi-
vidual HR types. Positive agreements were 60% or higher for 33 
of the 35 LR types with positive specimens in either batch. None 
of the discrepancies were statistically significant for any type 
(P < .05, McNemar). Five types (HPV3, 13, 28, 76, and 97) were 
not detected in either batch.
Agreement of TypeSeq With Linear Array and SPF10-LiPA for Individual 
Human Papillomavirus Types
We evaluated the agreement of TypeSeq with LA in SUCCEED 
and SPF10-LiPA in CVT. Comparing TypeSeq with LA in 
SUCCEED, 10 of 13 carcinogenic types had at least 80% posi-
tive agreement and HPV16 had 94% positive agreement (Table 
2). The 3 types with lower agreement were HPV51, 52, and 56; 
all showed higher detection with TypeSeq. Six types (HPV31, 
33, 35, 52, 56, and 58) showed a significantly higher positivity 
for TypeSeq among the discrepant results (McNemar, P < .05). 
There was high agreement for detecting overall HPV positivity, 
and positive agreement for detecting any HR type reached 95% 
between TypeSeq and LA (see Supplementary Table 2).
Positive agreement between TypeSeq and SPF10-LiPA was 
somewhat lower, with 4 types having at least 70% and 9 types 
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having at least 60% positive agreement (Table 3). The posi-
tive agreement for HPV16 reached 80%. The types with lower 
agreement were HPV35, 58, 59, and 68/73; all showed higher 
detection by TypeSeq. Five types (HPV39, 56, 58, 59, and 
68) showed a significantly higher positivity by TypeSeq among 
the discrepant results (P < .00001, McNemar), whereas HPV52 
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Figure 2. TypeSeq versus SPF10-LiPA positives by human papillomavirus (HPV) genotype for 2357 clinical specimens. The number of positive specimens are shown for 
SPF10-LiPA and TypeSeq for the 27 genotypes detectable by both assays. The genotypes uniquely detectable by TypeSeq are displayed as “TypeSeq Unique Genotypes”.
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Figure 1. TypeSeq versus Linear Array (LA) positives by human papillomavirus (HPV) genotype for 2804 clinical specimens. The number of positive specimens are shown 
for LA and TypeSeq for the 37 genotypes detectable by both assays. The genotypes uniquely detectable by TypeSeq are displayed as “TypeSeq Unique Genotypes”. Linear 
Array’s HPV55 positives are show as HPV44 according to the current PAVE classification. HPV68 represents results for the HPV68 lineages C to F (previously “68b”) detectable 
by LA. HPV82 represents a combined result for HPV82 and 82v (IS39), which are detected individually by both assays.
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Table 1. TypeSeq Reproducibility Testing on 558 CVT Clinical Specimens in Duplicatea
HPV Genotype
Number of Specimens %Agreement
R1−/R2− R1+/R2− R1−/R2+ R1+/R2+ Total Positive McNemar P Value
Any HPV 175 21 14 348 93.7 90.9 .31
Any HR-HPVb 313 12 5 228 97.0 93.1 .15
16/18 514 1 2 41 99.5 93.2 1
3 558 0 0 0 100.0 NE NE
6 544 2 0 12 99.6 85.7 .48
11 557 0 0 1 100.0 100.0 NE
13 558 0 0 0 100.0 NE NE
16 522 1 1 34 99.6 94.4 .48
18 548 0 1 9 99.8 90.0 1
26 555 0 0 3 100.0 100.0 NE
28 558 0 0 0 100.0 NE NE
30 535 3 3 17 98.9 73.9 .68
31 531 1 2 24 99.5 88.9 1
32 548 2 0 8 99.6 80.0 .48
33 546 1 0 11 99.8 91.7 1
34 547 1 2 8 99.5 72.7 1
35 543 0 1 14 99.8 93.3 1
39 528 2 1 27 99.5 90.0 1
40 546 2 3 7 99.1 58.3 1
42 536 6 0 16 98.9 72.7 .041
43 550 3 2 3 99.1 37.5 1
44 533 3 5 17 98.6 68.0 .72
45 541 2 0 15 99.6 88.2 .48
51 533 2 5 18 98.7 72.0 .45
52 510 2 1 45 99.5 93.8 1
53 529 4 3 22 98.7 75.9 1
54 541 2 4 11 98.9 64.7 .68
56 532 1 0 25 99.8 96.2 1
58 525 0 0 33 100.0 100.0 NE
59 530 7 1 20 98.6 71.4 .077
61 534 0 3 21 99.5 87.5 .25
62 534 1 3 20 99.3 83.3 .62
66 528 1 0 29 99.8 96.7 1
67 536 0 4 18 99.3 81.8 .13
68a 527 4 4 23 98.6 74.2 .72
68b 549 1 0 8 99.8 88.9 1
69 556 0 0 2 100.0 100.0 NE
70 533 2 3 20 99.1 80.0 1
71 540 0 1 17 99.8 94.4 1
72 551 0 2 5 99.6 71.4 .48
73 546 2 2 8 99.3 66.7 .62
74 528 6 2 22 98.6 73.3 .28
76 558 0 0 0 100.0 NE NE
81 540 3 0 15 99.5 83.3 .25
82 555 1 0 2 99.8 66.7 1
82v 547 1 1 9 99.6 81.8 .48
83 545 2 1 10 99.5 76.9 1
84 543 0 1 14 99.8 93.3 1
85 552 0 1 5 99.8 83.3 1
86 549 1 1 7 99.6 77.8 .48
87 535 3 2 18 99.1 78.3 1
89 538 4 1 15 99.1 75.0 .37
90 543 1 3 11 99.3 73.3 .62
91 543 0 0 15 100.0 100.0 NE
97 558 0 0 0 100.0 NE NE
114 543 3 3 9 98.9 60.0 .68
Abbreviations: CVT, Costa Rica Vaccine Trial; HPV, human papillomavirus; HR-HPV, high-risk HPV; NE, not evaluable; R1, replicate 1; R2, replicate 2. 
aClinical specimens were tested in duplicate by manual (R1) or automated (R2) processing.
 bHR-HPV represents HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.
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was significantly more positive in SPF10-LiPA (P  =  .03). The 
positive agreement between TypeSeq and SPF10-LiPA in the 
random draw of 1998 samples from both study arms was slightly 
lower for the types that were oversampled (see Supplementary 
Table 3). Positive agreement for detecting any HR type reached 
77% between TypeSeq and SPF10-LiPA (see Supplementary 
Table 4).
Human Papillomavirus Genotype Prevalence by TypeSeq and Linear Array 
in CIN3+ From SUCCEED
We compared the genotype prevalence in cervical precancer 
and cancer (CIN3+) by TypeSeq and LA (Table 4). Overall, 
there was high concordance between both assays for all 
genotypes. Cases with HPV39, 52, 56, and 58 showed a 
difference of at least 5 CIN3+ cases between both assays; 
TypeSeq detected more CIN3+ for all these types except for 
HPV39-positive cases, in which it detected fewer cases of 
CIN3+.
When comparing all TypeSeq-positive and all LA-positive 
women, the risk of CIN3+ was very similar for all genotypes. 
There was no significant difference in the risk of CIN3+ between 
the discrepant categories (TS−/LA+ vs TS+/LA−) for any geno-
type (P > .05).
Estimation of Vaccine Efficacy Based on TypeSeq Compared With SPF10-
LiPA Test Results
To evaluate the performance of TypeSeq for detecting viral 
endpoints in vaccine trials and population surveillance studies, 
we calculated vaccine efficiency of the bivalent HPV vaccine 
based on HPV genotyping with TypeSeq compared with the 
reference standard in CVT, SPF10-LiPA (Table 5). Vaccine effi-
ciency estimates were computed in a population naive to HPV 
Table 3. Agreement Between TypeSeq and SPF10-LiPA for 13 Carcinogenic Types Among 2357 Women in CVT
HPV 
Type
N 
SPF10
% 
SPF10
N 
TypeSeq
% 
TypeSeq
N 
Both+
% 
Both+
N SPF10+/
TypeSeq−
% SPF10+/
TypeSeq−
N SPF10− /
TypeSeq+
% SPF10− /
TypeSeq+
N Nei-
ther+
% Nei-
ther+
% Agree-
ment
% Positive 
Agreement
McNemar 
P Value
16 200 8.5 203 8.6 179 7.6 21 0.89 24 1.0 2133 90.5 98.1 79.9 .38
18 101 4.3 90 3.8 84 3.6 17 0.72 6 0.3 2250 95.5 99.0 78.5 .43
31 159 6.8 152 6.5 125 5.3 34 1.44 27 1.2 2171 92.1 97.4 67.2 .44
33 55 2.3 59 2.5 46 2.0 9 0.38 13 0.6 2289 97.1 99.1 67.7 .39
35 33 1.4 38 1.6 25 1.1 8 0.34 13 0.6 2311 98.1 99.1 54.4 .28
39 72 3.1 104 4.4 66 2.8 6 0.25 38 1.6 2247 95.3 98.1 60.0 <.00001
45 90 3.8 100 4.2 80 3.4 10 0.42 20 0.9 2247 95.3 98.7 72.7 .07
51 115 4.9 122 5.2 96 4.1 19 0.81 26 1.1 2216 94.0 98.1 68.1 .30
52 163 6.9 144 6.1 120 5.1 43 1.82 24 1.0 2170 92.1 97.2 64.2 .03
56 71 3.0 106 4.5 69 2.9 2 0.08 37 1.6 2249 95.4 98.4 63.9 <.00001
58 60 2.6 101 4.3 58 2.5 2 0.08 43 1.8 2254 95.6 98.1 56.3 <.00001
59 51 2.2 102 4.3 49 2.1 2 0.08 53 2.3 2253 95.6 97.7 47.1 <.00001
68/73 83 3.5 232 9.8 78 3.3 5 0.21 154 6.5 2120 89.9 93.3 32.9 <.00001
Abbreviations: CVT, Costa Rica Vaccine Trial; HPV, human papillomavirus.
Table 2. Agreement Between TypeSeq and Linear Array for 13 Carcinogenic Types Among 2804 Women in SUCCEED
HPV 
Type N LA % LA N TypeSeq
% 
TypeSeq N Both+
% 
Both+
N LA+/
TypeSeq−
% LA+/
TypeSeq−
N LA−/
TypeSeq+
% LA−/
TypeSeq+
N Nei-
ther+
% Nei-
ther+
% Agree-
ment
% Positive 
Agreement
McNemar 
P Value
16 1067 38.1 1052 37.6 1025 36.6 42 1.5 27 1.0 1707 60.9 97.5 93.7 .09
18 268 9.6 280 10.0 250 8.9 18 0.6 30 1.1 2503 89.4 98.3 83.9 .11
31 287 10.3 307 11.0 275 9.8 12 0.4 32 1.1 2482 88.6 98.4 86.2 .003
33 121 4.3 138 4.9 120 4.3 1 0.04 18 0.6 2662 95.0 99.3 86.3 .00004
35 175 6.3 191 6.8 167 6.0 8 0.3 24 0.9 2602 92.9 98.9 83.9 .004
39 238 8.5 230 8.2 216 7.71 22 0.8 14 0.5 2549 91.0 98.7 85.7 .24
45 208 7.4 210 7.5 189 6.75 19 0.7 21 0.8 2572 91.8 98.6 82.5 .87
51 314 11.2 321 11.5 266 9.5 48 1.7 55 2.0 2432 86.8 96.3 72.1 .55
52 273 9.7 345 12.3 250 8.92 23 0.8 95 3.4 2436 86.9 95.8 67.9 .0002
56 204 7.3 224 8.0 184 6.57 20 0.7 40 1.4 2557 91.3 97.9 75.4 .01
58 167 6.0 199 7.1 163 5.82 4 0.1 36 1.3 2598 92.8 98.6 80.3 <.00001
59 216 7.7 219 7.8 197 7.03 19 0.7 22 0.8 2563 91.5 98.5 82.8 .76
68a 96 3.4 103 3.7 90 3.21 6 0.2 13 0.5 2692 96.1 99.3 82.6 .17
Abbreviations: HPV, human papillomavirus; LA, Linear Array; SUCCEED, Study to Understand Cervical Cancer Endpoints and Early Determinants.
aHPV68 represents results for the lineages detectable by LA (C to F, formerly “68b”). TypeSeq results for HPV68 lineages A and B (formerly “68a”), which are uniquely detectable by TypeSeq, 
were excluded from this analysis.
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infections at the time of vaccination as well as the full analytic 
cohort for HPV16/18 (the types included in the bivalent vac-
cine), HPV31, 33, 45 (3 types that show cross-protection for 
the bivalent vaccine), and 7 other types that are typically not 
affected by the vaccine. The number of infections detected by 
both assays was similar. In all comparisons, there was no statis-
tically significant difference in VE as determined by TypeSeq 
compared with SPF10-LiPA, and the prespecified threshold for 
assay comparability was achieved in all population and HPV 
genotype groups.
DISCUSSION
TypeSeq is a novel, affordable, high-throughput NGS assay for 
detection of 51 HPV genotypes. We validated TypeSeq in over 
5100 cervical specimens from 2 large epidemiological studies. 
TypeSeq showed high agreement with 2 widely established 
HPV genotyping assays, LA and SPF10-LiPA. In a large study 
of cervical precancers, no difference in risk of CIN3+ associ-
ated with individual genotypes was observed between TypeSeq 
and LA. In a randomized controlled HPV vaccine trial, no dif-
ference in VE for vaccine types and cross-protective types was 
observed between TypeSeq and SPF10-LiPA.
Human papillomavirus genotyping is central to under-
standing natural histories of HPV-related diseases and to 
HPV-based prevention efforts [1, 22]. Natural history dif-
fers between genotypes with respect to HPV acquisition and 
progression to precancer [23, 24]. Most importantly, the risk 
of cancer differs substantially between individual genotypes 
[2]. However, currently, very few HPV genotyping assays 
are commercially available, and most established assays are 
costly and laborious, which has limited HPV genotyping par-
ticularly in large longitudinal population-based studies with 
multiple rounds of specimen sampling. More important, the 
performance of HPV assays needs to strike a delicate balance 
between sensitivity and specificity, so that all clinically impor-
tant infections, but not irrelevant minor infections or viral de-
positions, are detected.
We are now entering a new era of HPV-based prevention 
of cervical cancers, with 3 highly efficacious HPV vaccines 
available that cover different HPV types. Evaluation of VE is 
shifting to viral endpoints, which requires accurate and repro-
ducible HPV genotyping [11]. A  new focus of HPV vaccine 
studies evaluates efficacy and effectiveness of vaccination with 
fewer doses, particularly 1-dose vaccination [25]. Likewise, 
postvaccination surveillance requires affordable and reliable 
HPV genotyping of specimens from large populations.
At the same time, HPV genotyping is important to determine 
which types to include in HPV assays and which types to detect 
individually for additional risk stratification [1]. Given its com-
parable performance to LA, an assay that performs similarly to 
HPV assays approved for HPV screening [26], TypeSeq could 
also be evaluated as an assay for screening and triage.
TypeSeq can process up to 950 samples per batch. The turn-
around time for this batch size is 3 days, with a hands-on time 
of 12 hours. Human papillomavirus genotype calling is fully au-
tomated, and results are immediately exported into a spread-
sheet. All genotypes are reported individually, but the software 
can mask and group genotypes, allowing customization of the 
assay to specific needs.
To improve detection of HPV genotypes in multiple infec-
tions, the assay normalizes the input viral DNA over a wide 
range of concentrations. Therefore, the assay does not provide 
information about viral load. However, this is a minor limita-
tion since the clinical relevance of viral load is limited [27].
The unique features of TypeSeq, particularly the high 
throughput, low cost, and high accuracy, make it an attrac-
tive assay for many applications. It can provide reliable HPV 
genotyping for large natural history studies with multiple 
Table 4. Prevalence of HPV Genotypes in CIN3+ by TypeSeq and Linear Array
HPV 
Type TS+
TS+ 
CIN3+
Risk TS 
(%) LA+
LA+ 
CIN3+
Risk LA 
(%) TS−/LA−
TS−/
LA+
TS−/LA+ 
CIN3+
Risk TS−/
LA+a (%)
TS+/
LA−
TS+/LA− 
CIN3+
Risk TS+/
LA−a (%) TS+/LA+
TS+/LA+ 
CIN3+
Risk TS+/
LA+ (%)
16 1052 474 45.1 1067 476 44.6 1707 42 5 11.9 27 3 11.1 1025 471 46.0
18 280 75 26.8 268 74 27.6 2503 18 6 33.3 30 7 23.3 250 68 27.2
31 307 81 26.4 287 78 27.2 2482 12 2 16.7 32 5 15.6 275 76 27.6
33 138 39 28.3 121 35 28.9 2662 1 0 0.0 18 4 22.2 120 35 29.2
35 191 37 19.4 175 33 18.9 2602 8 2 25.0 24 6 25.0 167 31 18.6
39 230 27 11.7 238 33 13.9 2549 22 7 31.8 14 1 7.1 216 26 12.0
45 210 56 26.7 208 60 28.8 2572 19 9 47.4 21 5 23.8 189 51 27.0
51 321 43 13.4 314 40 12.7 2432 48 8 16.7 55 11 20.0 266 32 12.0
52 345 63 18.3 273 54 19.8 2436 23 7 30.3 95 16 16.8 250 47 18.8
56 224 28 12.5 204 21 10.3 2557 20 2 10.0 40 9 22.5 184 19 10.3
58 199 42 21.1 167 34 20.4 2598 4 0 0.0 36 8 22.2 163 34 20.9
59 219 38 17.4 216 39 18.1 2563 19 4 21.1 22 3 13.6 197 35 17.8
68 103 21 20.4 96 19 19.8 2692 6 0 0.0 13 2 15.4 90 19 21.1
Abbreviations: CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; LA, Linear Array; TS, TypeSeq.
aThe difference in risk between TS−/LA and TS+/LA− was not significant for any of the types (P > .5).
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sampling. We successfully evaluated TypeSeq in a randomized 
controlled vaccine trial, and, based on its performance, we plan 
to use it in future HPV vaccination studies. The performance of 
TypeSeq is similar to LA, a widely evaluated assay that has high 
agreement with clinical HPV tests like Cobas and Onclarity 
[28]. Further evaluation of TypeSeq as a clinical test for primary 
screening with partial genotyping is supported by our findings. 
Evaluation of other specimen types, such as anal and oral swab 
samples, as well as tissue specimens, using the assay is currently 
underway.
TypeSeq requires an infrastructure suitable for NGS tech-
nology and investment in sequencing equipment. However, 
these technologies are advancing quickly, and new robust 
equipment can now be made available in all regions of the 
world. Furthermore, smaller and more achievable NGS plat-
forms are now available that reduce up-front costs. Due to the 
highly integrated and automated workflow of the assay, tech-
nology transfer is feasible and is currently happening in other 
laboratories.
CONCLUSIONS
In summary, we have validated a novel NGS-based HPV 
genotyping assay that addresses a widespread need for high-
throughput, affordable HPV genotyping for research, surveil-
lance, and clinical management.
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